The new release (or update) yesterday was significant; data collected from 266 patient is much better than the data reported from 210 patients and DMC recommendation would be different if it's based on the latest result. EDGE will provide the final update of all 283 patients later this year. If the final data is consistent with the latest results, then I guess they have the option for continuing EG-1962 development beside merge/acquisition
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.